An Open Exploratory Study to Evaluate The Preliminary Efficacy of GH21 Combined With Primary Targeting or Immunotherapy in Patients With Advanced Solid Tumors Which Targeted or Immunotherapy Has Progressed
Latest Information Update: 04 Oct 2024
At a glance
- Drugs HBI 2376 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Suzhou Genhouse Bio
- 11 Jul 2024 Trial design changed to parallel assignment. Arms amended from 1 to 5.
- 11 Jul 2024 Status changed from not yet recruiting to recruiting.
- 22 Mar 2024 New trial record